GSK maintains lead in BCMA race with FDA panel’s recommendation

If FDA follows a Tuesday recommendation by ODAC, GSK’s belantamab mafodotin would be the first BCMA-targeted therapy to gain approval.

The unanimous vote by FDA’s Oncologic Drugs Advisory Committee in favor of the BCMA-targeting antibody-drug conjugate despite a risk of vision loss highlights the potential benefits of the first-in-class therapy for multiple myeloma patients.

In the

Read the full 555 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE